Blood Pressure After Endovascular Stroke Therapy-II

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 120 participants.

Also called NCT04116112

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 120 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04116112
Other papers using this trial's data
  • Blood Pressure Management After Endovascular Therapy for Acute Ischemic Stroke: The BEST-II Randomized Clinical Trial JAMA, 2023-09-05 DOI, PubMed 37668620, PMC10481231 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04116112. Randomized; single masking; primary purpose treatment. Start 2020-01-17 (actual); primary completion 2022-07-01 (actual). Results posted on 2023-10-12.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Blood Pressure After Endovascular Stroke Therapy-II
Acronym
BEST-II
Condition
Acute Stroke
Condition
Endovascular Thrombectomy
Intervention (Drug)
Nicardipine
Intervention (Drug)
Labetalol
Intervention (Drug)
Hydralazine
Lead sponsor
University of Cincinnati (class: other)
Collaborator
National Institute of Neurological Disorders and Stroke (NINDS) (class: US National Institutes of Health)
Collaborator
Vanderbilt University Medical Center (class: other)

Record details

Record id
cardio:ct-nct04116112
Content hash
4c075f37de528f179575efa9a3718a3bcd68846652f6a911fd8b74c56da427a8